Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)

Inclusion Criteria: * Age 18 or older; * Diagnosed with acute ischemic stroke; * Within 6 hours of onset; * Having received or plan to undergo intravenous thrombolytic therapy; * NIHISS score of 4 to 25 points at enrollment; * Signed informed consent. Exclusion Criteria: * mRS score greater than 1 point before the onset; * Receiving neuroprotective agents, such as edaravone, edaravone dextrocamphorol, butylphthalein, etc. after the onset; * Bleeding or other pathological brain disorders, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis), detected by CT/MRI; * History of clotting disorders, systemic bleeding, thrombocytopenia, or neutropenia; * Severe hepatic or renal insufficiency (severe hepatic insufficiency refers to the ALT or AST levels above 3 times the upper limit of normal; severe renal insufficiency refers to the creatinine levels above 2 times the upper limit of normal); * Allergic to Shuxuening injection or preparations containing ginkgo biloba (ginkgo biloba extract); * Women who are pregnant or breastfeeding, and women of childbearing age who have a negative pregnancy test but refuse to take effective contraceptive measures; * Participation in another clinical trial with an experimental product during the last 30 days; * Other participants deemed unsuitable for participation in this study by the investigator.